-
Al Jazeera English Launches in New York
Monday, August 1, 2011 - 11:42am | 136Al Jazeera English has become available for the first time to cable television viewers across New York. Two Million Subscribers to Time Warner Cable (Channel 92) and Verizon FiOS in the New York City region will be able to tune into global news coverage all day and through the night. This has been...
-
Defense and Security Stocks Trading Alert: Aerosonic, Kratos Defense & Security, Visualant, Irvine Sensors
Monday, August 1, 2011 - 11:06am | 772Point Roberts, WA - August 1, 2011 - Investorideas.com, an investor research portal covering multiple stock sectors including defense and security stocks, presents a sector close up on defense and security stocks for Friday's trading, July 29th. Aerosonic Corporation (AMEX: AIM) jumped 0.22 (7.03...
-
Friday's NASDAQ Top Percentage Gainers: Allied Healthcare, Opexa Therapeutics, ZOLL Medical, Sify Technologies
Monday, August 1, 2011 - 10:59am | 501POINT ROBERTS, August 1, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 29, 2011. On Friday, Allied Healthcare International's stock climbed 56%. Allied Healthcare International Inc. (NASDAQ: AHCI...
-
Stifel Nicolaus Maintains Buy on Amgen
Monday, August 1, 2011 - 9:29am | 84Stifel Nicolaus is out with its report today on Amgen (NASDAQ: AMGN), maintaining Buy. In its report, Stifel Nicolaus writes, "To value Amgen we relied upon a DCF analysis, using our updated bottom-up, market-based model and its related adjusted EBIT, resulting in our one-year target price of $67...
-
CytRx's INNO-206 in Combination Therapy Induces Complete Remissions in Aggressively Growing Ovarian Cancer Tumor Model
Monday, August 1, 2011 - 8:35am | 265CytRx Corporation (Nasdaq: CYTR) today announced the achievement of complete remissions in aggressively growing in vivo ovarian cancer tumors treated with a combination of low doses of CytRx's tumor-targeted albumin-binding doxorubicin conjugate INNO-206 and the commonly prescribed cancer treatment...
-
Earnings Roundup
Monday, August 1, 2011 - 8:34am | 705Allstate Corp (NYSE: ALL) swung to a second quarter loss on Monday. Allstate reported a quarterly loss of $642 million, or $1.19 per share, versus a profit of $441 million, or $0.27 per share, in the year-earlier period. Its catastrophe losses surged to $2.34 billion, from $96.8 billion, in the...
-
Alnylam Completes ALN-VSP Phase I Trial in Patients with Liver Cancer
Monday, August 1, 2011 - 8:05am | 400Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. “We are very pleased with the results of our ALN-VSP Phase I trial that...
-
Protalix Submits Reply to FDA Complete Response Letter for Taliglucerase Alfa and Reports Top-Line Results from the Company's Switchover Trial
Monday, August 1, 2011 - 8:03am | 158Protalix BioTherapeutics, Inc. (NYSE: PLX), announced today that it has submitted its reply to the Complete Response Letter issued in February 2011 by the U.S. Food and Drug Administration after its review of the Company's New Drug Application for taliglucerase alfa. Taliglucerase alfa, the...
-
ARIAD Announces That Merck Has Submitted for Approval of Ridaforolimus, an Investigational mTOR Inhibitor, in the EU
Monday, August 1, 2011 - 7:38am | 131ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its ridaforolimus partner, Merck (NYSE: MRK), has submitted a marketing authorization application for ridaforolimus with the European Medicines Agency. The submission occurred on July 29, 2011 and marks the start of Merck's global...
-
ARIAD Announces That Its Partner, Merck, Has Submitted for Approval of Ridaforolimus, an Investigational mTOR Inhibitor, in the European Union
Monday, August 1, 2011 - 7:35am | 261ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application for ridaforolimus with the European Medicines Agency (EMA). The submission occurred on July 29, 2011 and marks the start of Merck's global submission...
-
UPDATE: Acorda Therapeutics Reports Weaker-Than-Expected Q2 Earnings
Monday, August 1, 2011 - 7:26am | 58Acorda Therapeutics Inc (NASDAQ: ACOR) released its results for the second quarter on Monday. Acorda Therapeutics reported its quarterly earnings at $0.01 per share. ACOR's revenue climbed 52.6% y/y to $65.3 million. Analysts were expecting earnings of $0.12 per share on revenue of $66.04 million...
-
Cubist Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Urinary Tract Infections
Monday, August 1, 2011 - 7:10am | 90Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of a pivotal Phase 3 trial of CXA-201 in patients with complicated urinary tract infections. CXA-201 is being developed as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in...
-
Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Biotoscana Farma S.A. for Commercialization of Fanapt in Argentina.
Monday, August 1, 2011 - 7:03am | 190Vanda Pharmaceuticals (NASDAQ: VNDA) today announced its exclusive license agreement with Argentina-based Biotoscana Farma S.A., a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt ™ in Argentina. "We are very excited to achieve...
-
Piper Jaffray Reviews Products Lines at Amgen
Monday, August 1, 2011 - 6:47am | 132Piper Jaffray has published a report on Amgen (NASDAQ: AMGN) covering individual product lines. In the report, Piper Jaffray wrote, "Amgen reported 2Q earnings that were well above consensus expectations, with most major product lines coming in ahead and Epogen sales meeting Street forecasts. Both...
-
ISI Modifies PT on Celgene to $67
Monday, August 1, 2011 - 3:22am | 64ISI modified its price target on Celgene (NASDAQ: CELG) to $67. At the same time, the rating agency left its price target on United Therapeutics (NASDAQ: UTHR) unchanged at $65. On Friday, Celgene lost 1.1% of its value to finish the week at $59.30, while UTHR rose 1.07% to end the day at $57.38.